What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners. The agreement, which also includes a team of biotech executives,
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Hand crews will work over the next year to form a new fuel modification zone in the Bluebird Canyon area of Laguna Beach, the ...
EST Bluebird Bio (BLUE) trading resumesDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving strong buy ...
The transaction agreement unreasonably limits competing transactions for bluebird by imposing a significant penalty if bluebird accepts a competing bid. We are investigating the conduct of bluebird's ...
Penny and Fritz Brandau, members of the Black River Audubon Society and the Ohio Bluebird Society, will give a presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback